These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23360812)

  • 21. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
    Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
    Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
    Manai M; Doghri R; Finetti P; Mrad K; Bouabsa R; Manai M; Birnbaum D; Bertucci F; Charfi L; Driss M
    In Vivo; 2020; 34(1):177-184. PubMed ID: 31882477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
    Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
    Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M; Høgdall CK; Mosgaard BJ
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized Treatment of Patients With Early-Stage Epithelial Ovarian Cancer After Incomplete Initial Surgery.
    Tu H; Xiong Y; Huang H; Huang Y; Wan T; Deng T; Liu J
    Int J Gynecol Cancer; 2016 Jan; 26(1):73-81. PubMed ID: 26569056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
    Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
    Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study.
    Bao L; Ding Y; Cai Q; Ning Y; Hu W; Xue X; Sun H; Hua K; Zhou X; Yi X
    Int J Gynecol Cancer; 2016 Mar; 26(3):424-30. PubMed ID: 26825825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
    Huang LP; Yu YH; Sheng C; Wang SH
    Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment failure in endometrial carcinoma.
    Huang HJ; Tang YH; Chou HH; Yang LY; Chao A; Huang YT; Lin G; Liu FY; Chang TC; Lai CH
    Int J Gynecol Cancer; 2014 Jun; 24(5):885-93. PubMed ID: 24819657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.
    Selle F; Pautier P; Lhommé C; Viens P; Fabbro M; Lokiec F; Gligorov J; Richard S; Provent S; Soares DG; Lotz JP
    Chemotherapy; 2016; 61(1):15-22. PubMed ID: 26528705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
    Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
    Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perioperative morbidity and mortality in octogenarians with ovarian cancer.
    Walters CL; Schneider KE; Whitworth JM; Fauci JM; Smith HJ; Barnes MN; Straughn JM
    Int J Gynecol Cancer; 2013 Jul; 23(6):1006-9. PubMed ID: 23714708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.